Introduction to SWISS IMMUNE & Amedioo Disease Areas ©

“We only work where we and our technologies work best.”

We possess an independent and thorough understanding of our technologies from leading Universities in Europe and US / Boston (Vienna, MHH Hannover, Heidelberg, Freiburg iB, Tübingen, Giessen, Dana Faber Institute in Boston, USA). We are managed based from ETH Zurich (Sara Maria, 18) and Lucerne, Meggen (Christian), Switzerland, with an experienced management team (Head of EMEA Oncology of AstraZeneca, London, Global Executive VP & Executive Head of Europe, Parexel (CRO), in Berlin, Germany). We took the best of our networks in oncology from 3 decades, too. From EMEA and USA. We build on quality and ethics. Ethics and quality, in the end.

We have applied AI immunology over 5 years now to transform today’s major understanding and limitations of delivering cancer care in practical life. Life is not linear. It is complex. The human brain structures and learned to keep it linear and step-by-step mostly. The main challenge in cancer care is “step-by-step” in our belief. And sequential, over a long time of treatment. This is profitable to many. A patient has the shock and the experience of normally one case – his or hers. We work AI driven, integrated, not linear and only (!) where we can “cure or move far closer to curing cancer types and life-threatened patients” (CR / R). We started at 23% of cure in melanoma (sarcoids, CR) in horses and are now above 93%. Treating cancer is not trivial – if one wants to cure. Cure can be quick or mid-term, long-term results count.

The governing company is SWISS IMMUNE EDC and NEMOO AI Value Builders EDC AG, Lucerne, Switzerland. We started years ago – and put it together in 2021. We structured strategies, indications, solutions and investments – and can satisfy all parties, investors and science included. There is enough for all to share – as we can see today.

Besides 3 first key areas, pelvic, skin-melanoma and thoracic cancers, we also separated out “Top 3 – Major Cancer Challenges” in “meedioo.com” to be built with future US and EU scientific centers and leaders – and partners – as competition of today’s therapies is huge and partnerships in these major cancer types are critical.

We also founded an own “cancer specific” NEMOO AI companies’ EDC clinical trials organisation (CRO). Because we could not get our services with AI needed at affordable costs and quality, speed (SWISSEXEL). So we are supported by SWISSEXEL, an AI and pure-play IO (immuno-oncology) driven, “smart AI” development engine, with public university hospitals (non private clinics) for AI driven, asset development including commercialisation. We therefore have a strategic partnership with a leading AI software provider (FDA, EMA) in oncology and immunology.

Driving value for investors: Based on our experience and knowledge, integrating AI deeper and smarter than others (swissexel.com), we develop our drug plans 2-3 years faster at 30-35% of standard costs only. This gives investors an additional (X-) multiplier on top for their financial returns (ROI). Hence, x 3.5 to above x 5.0. So a 2.5 – fold ROI can become a 5-10 fold return, just by “faster and at lower costs”. Simple mathematics, SWISS IMMUNE & SWISSEXEL.

We assess with technologies, structure and select cancer types. We aspire complete “financing end-to-end” until positive Phase II results or until other endpoints (e.g. exits, partnering, pre-IPOs or sale of indications after 1st marketing authorisations).

We represent an EDC – an Ethics Driven Company, a new concept for investing into hightech and breakthrough technologies (University of Zurich). Our financial plan is our business plan – and we track and report. We live honesty, transparency, smartness, excellence in what we do, openness and “rapid team-work”.

We deliver quality, precision & team-work